Mark Bustoros, MD, discusses how the use of genomic predictors in multiple myeloma (MM) allows for a better understanding of who will progress.
VIDEO: :49 Seconds
These risk models provide a way classify patients' needs according to their risks.
It also helps doctors and clinicians gain more accurately predict who is most likely to progress. By understanding the risks, patients and providers can work together more closely to determine the best approach to treatment.
This interview was recorded at the International Myeloma Workshop (IMW) 2019, held in Boston, MA.